AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34356039 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-3L scores in patients with confirmed sarcopenia
Number of subjects: 81
Study 34356039 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke duration as a factor for confirmed sarcopenia
Number of subjects: 81
Study 34356046 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide SNP-level analysis in patients with 22q11.2DS
Number of subjects: 5
Study 34356046 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide SNP-level analysis in patients without 22q11.2DS
Number of subjects: 5
Study 34356046 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-level analysis in patients with 22q11.2DS
Number of subjects: 5
Study 34356046 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-level analysis in patients without 22q11.2DS
Number of subjects: 5
Study 34356046 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene set analysis in patients with 22q11.2DS
Number of subjects: 5
Study 34356046 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene set analysis in patients without 22q11.2DS
Number of subjects: 5
Study 34357432 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative oxygen saturation measured by laser-Doppler spectrophotometry
Number of subjects: 34
Study 34357432 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative minimal value of oxygen saturation
Number of subjects: 34
Study 34357478 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 313
Study 34357478 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 313
Study 34357478 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive fluid balance
Number of subjects: 313
Study 34357478 — intervention group
Group type: COMPARATOR
Intervention: AKI patients
Number of subjects: 313
Study 34357478 — intervention group
Group type: COMPARATOR
Intervention: Dialysis dependence
Number of subjects: 313
Study 34357478 — intervention group
Group type: COMPARATOR
Intervention: Renal recovery
Number of subjects: 313
Study 34357478 — intervention group
Group type: COMPARATOR
Intervention: Chronic kidney disease (CKD)
Number of subjects: 313
Study 34357561 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (once-daily)
Number of subjects: 2989
Study 34357561 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2989
Study 34357785 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34357790 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching Kitchen Medical Groups Visit with an eHealth Platform
Number of subjects: 0
Study 34358399 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid blood test combining GFAP and UCH-L1 measurements
Number of subjects: 1918
Study 34358484 — intervention group
Group type: EXPERIMENTAL
Intervention: Infigratinib 125 mg orally once daily for 21 days of 28-day cycles until disease progression, intolerance, withdrawal of consent, or death.
Number of subjects: 108
Study 34358484 — intervention group
Group type: EXPERIMENTAL
Intervention: Infigratinib
Number of subjects: 108
Study 34358493 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34358495 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34358835 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS patients
Number of subjects: 26
Study 34358839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal Dysfunction Score (GIDS)
Number of subjects: 540
Study 34358839 — intervention group
Group type: COMPARATOR
Intervention: Citrulline and intestinal fatty acid-binding protein (I-FABP) measurements
Number of subjects: 540
Study 34359014 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric amygdala and hippocampus volume
Number of subjects: 81
Study 34359014 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcortical shape analysis
Number of subjects: 81
Study 34359014 — intervention group
Group type: COMPARATOR
Intervention: Striatal anatomy
Number of subjects: 81
Study 34359048 — intervention group
Group type: EXPERIMENTAL
Intervention: SIACI of bevacizumab (15 mg/kg) and cetuximab (200 mg/m2)
Number of subjects: 13
Study 34359048 — intervention group
Group type: EXPERIMENTAL
Intervention: SIACI of bevacizumab and cetuximab
Number of subjects: 13
Study 34360133 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-sensor bracelets collecting passive data (acceleration, electrodermal activity, blood volume pulse) and active data via smartphone questionnaires.
Number of subjects: 60
Study 34360133 — intervention group
Group type: COMPARATOR
Intervention: Healthy control couples (not specified intervention).
Number of subjects: 60
Study 34360156 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccines (including booster doses)
Number of subjects: 0
Study 34360198 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cortisol reactivity percentile (<25th)
Number of subjects: 551
Study 34360198 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CRF and high BP
Number of subjects: 551
Study 34360198 — intervention group
Group type: EXPERIMENTAL
Intervention: Black ethnicity
Number of subjects: 551
Study 34360513 — intervention group
Group type: EXPERIMENTAL
Intervention: High maternal physical activity (PA)
Number of subjects: 223
Study 34360513 — intervention group
Group type: COMPARATOR
Intervention: Low maternal physical activity (PA)
Number of subjects: 223
Study 34361902 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements and exercise training
Number of subjects: 0
Study 34362196 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) intervention
Number of subjects: 0
Study 34362196 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34362217 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic vulnerability biomarkers (Hs-CRP, MMP-9, IL-6, I-CAM, V-CAM, E-selectin) measured at 1 hour after revascularization
Number of subjects: 225
Study 34362310 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based ART delivery (CAD) model
Number of subjects: 2000
Study 34362310 — intervention group
Group type: COMPARATOR
Intervention: Multi-month dispensing (MMD)
Number of subjects: 2000
Study 34362415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Power (MP)
Number of subjects: 825
Study 34362415 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving Pressure (ΔP)
Number of subjects: 825
Study 34362415 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing quartiles of Mechanical Power (MP)
Number of subjects: 825
Study 34362494 — intervention group
Group type: EXPERIMENTAL
Intervention: C-CAR011 infusion following lympho-depletion
Number of subjects: 6
Study 34362494 — intervention group
Group type: EXPERIMENTAL
Intervention: C-CAR011 infusion
Number of subjects: 6
Study 34363189 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 90
Study 34363189 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (started within first 5 days from symptoms onset)
Number of subjects: 90
Study 34363189 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (started later than 5 days from symptoms onset)
Number of subjects: 90
Study 34363393 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace environment
Number of subjects: 45
Study 34363393 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of meaning
Number of subjects: 45
Study 34363393 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication issues
Number of subjects: 45
Study 34363393 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily interactions
Number of subjects: 45
Study 34363598 — intervention group
Group type: EXPERIMENTAL
Intervention: Current therapy and clinical practices for PDN
Number of subjects: 1547
Study 34363598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting blood glucose (FBG)
Number of subjects: 1547
Study 34363598 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral artery disease (PAD)
Number of subjects: 1547
Study 34363598 — intervention group
Group type: EXPERIMENTAL
Intervention: Opium therapies
Number of subjects: 1547
Study 34363598 — intervention group
Group type: EXPERIMENTAL
Intervention: Contradiction of first-line guideline recommendation for pain relief
Number of subjects: 1547
Study 34363598 — intervention group
Group type: EXPERIMENTAL
Intervention: Contradiction of second-line guideline recommendation for opium dosage form
Number of subjects: 1547
Study 34363769 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral low-molecular-weight or unfractionated heparin for 72 hours followed by oral dabigatran 150 mg twice per day
Number of subjects: 402
Study 34364096 — intervention group
Group type: EXPERIMENTAL
Intervention: FilmArray Pneumonia Panel
Number of subjects: 0
Study 34364096 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice for rational use of FilmArray Pneumonia Panel
Number of subjects: 0
Study 34364311 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 infection
Number of subjects: 32
Study 34364311 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccination
Number of subjects: 32
Study 34364311 — intervention group
Group type: COMPARATOR
Intervention: Uninfected, non-vaccinated controls
Number of subjects: 32
Study 34364365 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial color-coded duplex sonography assessment of cerebrovascular reactivity to carbon dioxide
Number of subjects: 30
Study 34364384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor mothers providing psychosocial and other support as a PMTCT intervention.
Number of subjects: 118
Study 34364384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor mothers as relatable role models for WLHIV.
Number of subjects: 118
Study 34364384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor mothers' services delivery preference.
Number of subjects: 118
Study 34364384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor mother needs identified.
Number of subjects: 118
Study 34364384 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall acceptability of mentor mothers as a PMTCT intervention.
Number of subjects: 118
Study 34364384 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges faced by mentor mothers and clients.
Number of subjects: 118
Study 34364652 — intervention group
Group type: EXPERIMENTAL
Intervention: PATH checklist
Number of subjects: 587
Study 34364770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenestrated/branched endografts (F/BEVAR)
Number of subjects: 85
Study 34365516 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T therapy
Number of subjects: 254
Study 34365516 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T therapy with consolidative allo-HSCT
Number of subjects: 254
Study 34365644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg (twice daily)
Number of subjects: 7250
Study 34365799 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmethylamine-N-Oxide (TMAO) levels
Number of subjects: 195
Study 34365799 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic dysfunction
Number of subjects: 195
Study 34365878 — intervention group
Group type: EXPERIMENTAL
Intervention: KA2237, a dual p110β/p110δ inhibitor, administered orally.
Number of subjects: 21
Study 34366107 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratinocyte-fibroblast interactions
Number of subjects: 0
Study 34366107 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 34366147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular senescence
Number of subjects: 0
Study 34366734 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 34366734 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine omega-3 (n-3) fatty acid supplementation
Number of subjects: 0
Study 34366734 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 34366804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 0
Study 34366804 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Control Training (CCT)
Number of subjects: 0
Study 34366928 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS stimulants (predominantly OROS-Methylphenidate, up to 54 mg per day)
Number of subjects: 0
Study 34367149 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical stem cell transplantation (haplo SCT) and dinutuximab (anti-GD2 antibody)
Number of subjects: 0
Study 34367680 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab treatment for cytokine release syndrome (CRS) in COVID-19-induced pneumonia
Number of subjects: 51
Study 34367728 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride (HDC) and low-dose interleukin-2 (IL-2)
Number of subjects: 84
Study 34367728 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride (HDC)
Number of subjects: 84
Study 34368242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Shock Wave Therapy
Number of subjects: 0
Study 34368242 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34368249 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Serum Levels of Soluble ST2
Number of subjects: 0
Study 34368662 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infection with intestinal parasites
Number of subjects: 0
Study 34368662 — intervention group
Group type: COMPARATOR
Intervention: No co-infection with intestinal parasites
Number of subjects: 0
Study 34369075 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastmilk feeding
Number of subjects: 151
Study 34369075 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF)
Number of subjects: 151
Study 34369075 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous EBF for at least 3 months
Number of subjects: 151
Study 34369075 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding category transitions
Number of subjects: 151
Study 34369075 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental formula use
Number of subjects: 151
Study 34369165 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors
Number of subjects: 5006
Study 34369165 — intervention group
Group type: COMPARATOR
Intervention: LDL-C cohort
Number of subjects: 5006
Study 34369165 — intervention group
Group type: COMPARATOR
Intervention: Younger patients
Number of subjects: 5006
Study 34369165 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 5006
Study 34369165 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 5006
Study 34369165 — intervention group
Group type: COMPARATOR
Intervention: Education
Number of subjects: 5006
Study 34369187 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol (HDL-C) level
Number of subjects: 1864
Study 34369187 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation defined by hs-CRP level of ≥1.0 mg/L
Number of subjects: 1864
Study 34369187 — intervention group
Group type: COMPARATOR
Intervention: Overall incidence of primary outcome
Number of subjects: 1864
Study 34369198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio-Ankle Vascular Index (CAVI)
Number of subjects: 2932
Study 34369198 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2932
Study 34369333 — intervention group
Group type: COMPARATOR
Intervention: CON (25 g whey protein hydrolysate)
Number of subjects: 18
Study 34369333 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW (25 g whey protein hydrolysate + 3179 mg Capolac®)
Number of subjects: 18
Study 34369333 — intervention group
Group type: EXPERIMENTAL
Intervention: MED (25 g whey protein hydrolysate + 6363 mg Capolac®)
Number of subjects: 18
Study 34369333 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH (25 g whey protein hydrolysate + 9547 mg Capolac®)
Number of subjects: 18
Study 34369385 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch meal in IS subjects
Number of subjects: 16
Study 34369385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinner meal in IR subjects
Number of subjects: 16
Study 34369385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal and next-morning hyperlipidemia in IR subjects
Number of subjects: 16
Study 34369388 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 31
Study 34369388 — intervention group
Group type: COMPARATOR
Intervention: Healthy-weight controls
Number of subjects: 31
Study 34369413 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboelastography assay (TEG-6s)
Number of subjects: 119
Study 34369416 — intervention group
Group type: EXPERIMENTAL
Intervention: p.Pro51Ser (p.P51S) variant carriers
Number of subjects: 111
Study 34369416 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hearing aids (PTA ≥ 40 dB HL)
Number of subjects: 111
Study 34369416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implants (PTA ≥ 70 dB HL)
Number of subjects: 111
Study 34369416 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaural asymmetry and variability assessment
Number of subjects: 111
Study 34369417 — intervention group
Group type: EXPERIMENTAL
Intervention: C-VEMP activity
Number of subjects: 111
Study 34369417 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric responses (water irrigation)
Number of subjects: 111
Study 34369417 — intervention group
Group type: EXPERIMENTAL
Intervention: vHIT VOR-gains
Number of subjects: 111
Study 34369417 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing deterioration in female carriers
Number of subjects: 111
Study 34369417 — intervention group
Group type: EXPERIMENTAL
Intervention: VNG caloric gain (water irrigation)
Number of subjects: 111
Study 34369417 — intervention group
Group type: EXPERIMENTAL
Intervention: Three SCCs
Number of subjects: 111
Study 34369417 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of C-VEMP response
Number of subjects: 111
Study 34369417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular decline preceding hearing deterioration
Number of subjects: 111
Study 34369424 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (MPA) 150-mg intramuscular injection
Number of subjects: 62
Study 34369424 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz-based HIV therapy and rifampicin plus isoniazid
Number of subjects: 62
Study 34369424 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analyses of 28 polymorphisms in 14 genes
Number of subjects: 62
Study 34369424 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot MPA dosing frequency
Number of subjects: 62
Study 34369424 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6 metabolizer or NAT2 acetylator status
Number of subjects: 62
Study 34369447 — intervention group
Group type: EXPERIMENTAL
Intervention: PwS walking over a computerized treadmill system at self-selected speed
Number of subjects: 22
Study 34369451 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity measured using Actigraph GT3x accelerometer, average 5876 ± 3180 steps per day.
Number of subjects: 89
Study 34369451 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender, being 70 years of age and older, and greater reported mobility problems.
Number of subjects: 89
Study 34369451 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 89
Study 34369451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic-related reduction in exercise habits and rehabilitation attendance.
Number of subjects: 89
Study 34369983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular surface microbiome sequencing using whole-metagenome shotgun sequencing and tear proteome identification using chromatography tandem mass spectrometry.
Number of subjects: 20
Study 34369983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular surface microbiome
Number of subjects: 20
Study 34370076 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg BID
Number of subjects: 36
Study 34370076 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg BID with rosuvastatin 20 mg
Number of subjects: 36
Study 34370076 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg BID with oral contraceptives
Number of subjects: 36
Study 34370076 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg
Number of subjects: 36
Study 34370076 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives (ethinylestradiol 30 µg + levonorgestrel 150 µg)
Number of subjects: 36
Study 34370116 — intervention group
Group type: EXPERIMENTAL
Intervention: P/FP ratio with PEEP levels > 5 cmH2O
Number of subjects: 3442
Study 34370116 — intervention group
Group type: COMPARATOR
Intervention: P/F ratio
Number of subjects: 3442
Study 34370760 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D CAD/CAM designed Boston 3D-brace
Number of subjects: 170
Study 34370760 — intervention group
Group type: COMPARATOR
Intervention: Standard Boston brace
Number of subjects: 170
Study 34370760 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (3D CAD/CAM and Standard Boston brace)
Number of subjects: 170
Study 34370839 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticancer drugs (40 drugs significantly associated with diLQT)
Number of subjects: 18441659
Study 34370839 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticancer drugs (9 drugs associated with VA without diLQT)
Number of subjects: 18441659
Study 34370839 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinase inhibitors (20/49 drugs)
Number of subjects: 18441659
Study 34370839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapies (4/49 drugs)
Number of subjects: 18441659
Study 34370839 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapies (3/49 drugs)
Number of subjects: 18441659
Study 34370839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxics (12/49 drugs)
Number of subjects: 18441659
Study 34370839 — intervention group
Group type: EXPERIMENTAL
Intervention: Miscellaneous (10/49 drugs)
Number of subjects: 18441659
Study 34370839 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticancer drugs reporting
Number of subjects: 18441659
Study 34370839 — intervention group
Group type: EXPERIMENTAL
Intervention: VigiBase signals
Number of subjects: 18441659
Study 34370839 — intervention group
Group type: EXPERIMENTAL
Intervention: New signals from drugs
Number of subjects: 18441659